AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37919697
Drug: Daily combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily combined oral contraceptive (daily pills)
Trial: 37919697
Drug: Bi-monthly injectable
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-monthly injectable contraceptive (injectable)
Trial: 37919697
Drug: Daily pills
RxNorm normalized name: Daily Hist Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pills
Trial: 37919940
Drug: Ranibizumab intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab intravitreal therapy
Trial: 37920150
Drug: Covid-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covid-19 convalescent plasma (4 units, 200-220 mL/unit, 2 units/day over two consecutive days)
Trial: 37920192
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (upload glucose data weekly for 4 months, receive support from diabetes care team)
Trial: 37920410
Drug: 0.15% Azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% Azelastine hydrochloride (AZE), two sprays per nostril twice daily for 4 weeks
Trial: 37920410
Drug: 0.10% Azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10% Azelastine hydrochloride (AZE), dosage not specified
Trial: 37920522
Drug: Algorithm Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm Guided Treatment (AGT)
Trial: 37920733
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for the transdiagnostic treatment of EDs
Trial: 37920833
Drug: Betahistine 48
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 48 mg with selegiline (5 mg/d for 7 days)
Trial: 37920833
Drug: Betahistine 48
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 48 mg alone
Trial: 37920858
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment on days 1 and 2 in addition to standard postoperative pain management
Trial: 37920963
Drug: Cannabidiol 150-300
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 150-300 mg/day
Trial: 37920963
Drug: Cannabidiol 300
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 300 mg/day
Trial: 37921006
Drug: ADT ON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT ON (continuation of antiarrhythmic drug therapy)
Trial: 37921006
Drug: ADT OFF
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT OFF (discontinuation of antiarrhythmic drug therapy)
Trial: 37921410
Drug: PVRV-NG2 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV-NG2 (three different doses)
Trial: 37921522
Drug: Perfluorohexyloctane (PFHO)
DrugBank: Perfluorohexyloctane (DB17823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfluorohexyloctane (PFHO) ophthalmic drop, 1 drop 4 times daily for 52 weeks
Trial: 37921599
Drug: Laparoscopic Visceral-Peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic Visceral-Peritoneal Debulking (L-VPD)
Trial: 37921755
Drug: Giredestrant (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant (10, 30, 90, or 250 mg)
Trial: 37921755
Drug: Giredestrant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant (100 mg) + Palbociclib (125 mg) ± LHRH agonist
Trial: 37921755
Drug: Giredestrant (single-agent)
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant (single-agent) ± LHRH agonist
Trial: 37921755
Drug: Giredestrant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant (100 mg)
Trial: 37921846
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (VCT-based problem-solving individual therapy)
Trial: 37922035
Drug: Antioxidant drug
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant drug apocynin
Trial: 37922279
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music intervention combined with progressive muscle relaxation (self-practice daily for three weeks)
Trial: 37922438
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PSMA-targeting alpha emitter via antibody delivery
Trial: 37922442
Drug: Adjuvant Hyperthermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Hyperthermic Intraperitoneal Chemotherapy
Trial: 37922692
Drug: Targeted therapy/cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy/cancer immunotherapy
Trial: 37922910
Drug: Anti-PD-1 immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 immunotherapy combined with standard-of-care chemo-hormonal therapy
Trial: 37922910
Drug: Standard-of-care chemo-hormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemo-hormonal therapy
Trial: 37922930
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of lutetium-177
Trial: 37923161
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg/day, N = 45)
Trial: 37923345
Drug: Fortified balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified balanced energy-protein (BEP) supplement during pregnancy and lactation
Trial: 37923987
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (SCRT) followed by four cycles of FOLFOX (oxaliplatin, 5-fluorouracil, and folinic acid) as a neoadjuvant treatment.
Trial: 37923987
Drug: SCRT followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCRT followed by FOLFOX chemotherapy.
Trial: 37924084
Drug: Inhalation LPS
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation LPS challenge
Trial: 37924247
Drug: Online exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online exposure and response prevention therapy for 10 weeks
Trial: 37924833
Drug: Subcutaneous TV-46000
RxNorm normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous TV-46000 once monthly
Trial: 37924833
Drug: Subcutaneous TV-46000
RxNorm normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous TV-46000 once every 2 months
Trial: 37924833
Drug: Subcutaneous TV-46000
RxNorm normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous TV-46000 (both groups)
Trial: 37924841
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure within the past 30 days (high-risk antibiotics p=0.011 and low-risk antibiotics p=0.0004)
Trial: 37924841
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure (adjusted odds ratio 2.75 [95% CI 1.22-6.16]) and male sex (2.75 [1.24-6.08])
Trial: 37924856
Drug: MNS 10
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNS 10 mg
Trial: 37925316
Drug: LVRNA009 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVRNA009 (25, 50, and 100 μg)
Trial: 37925363
Drug: Ledipasvir/Sofosbuvir (LDV/SOF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir (LDV/SOF) 45/200 mg once-daily orally for 12 weeks (chemotherapy treatment group)
Trial: 37925471
Drug: Tenapanor 5
RxNorm normalized name: tenapanor 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenapanor 5 mg twice daily (up to 30 mg twice daily)
Trial: 37925471
Drug: Tenapanor 5
RxNorm normalized name: tenapanor 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenapanor 5 mg twice daily
Trial: 37925512
Drug: Lung ultrasound
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound (LUS) guided surfactant therapy
Trial: 37925512
Drug: Standard surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surfactant therapy
Trial: 37927075
Drug: PCV13 Control
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 Control followed by a single supplemental dose of cPCV7 at 13 months
Trial: 37927936
Drug: Nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel plus gemcitabine (GnP-NAT), 125 mg/m²
Trial: 37928549
Drug: Tixagevimab/Cilgavimab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixagevimab/Cilgavimab 300 mg IV
Trial: 37928549
Drug: Tixagevimab/Cilgavimab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixagevimab/Cilgavimab 300 mg IM
Trial: 37928549
Drug: Tixagevimab/Cilgavimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixagevimab/Cilgavimab 600 mg IV
Trial: 37928549
Drug: Regdanvimab 40
RxNorm normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Regdanvimab 40 mg/kg IV
Trial: 37928891
Drug: Oral bemnifosbuvir
RxNorm normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bemnifosbuvir (AT-527)
Trial: 37928895
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (PC)
Trial: 37928925
Drug: Relapse prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse prevention (RP) therapy based on cognitive behavioral treatment (CBT), comprising five to seven 45-min sessions over a period of 5 to 7 weeks.
Trial: 37929672
Drug: Mirtazapine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (target 45 mg)
Trial: 37929672
Drug: Carbamazepine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (target 300 mg)
Trial: 37929770
Drug: Long-term home
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term home exercise program, details on dosage and duration not specified.
Trial: 37929952
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg plus NUC
Trial: 37930156
Drug: Nemtabrutinib 65
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemtabrutinib 65 mg daily
Trial: 37930156
Drug: Nemtabrutinib (varied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemtabrutinib (varied doses 5 to 75 mg once daily)
Trial: 37930244
Drug: High-dose protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose protein (≥ 2.2 g/kg/d)
Trial: 37930244
Drug: Usual-dose protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-dose protein (≤ 1.2 g/kg/d)
Trial: 37930669
Drug: Brexpiprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (2 mg/d or 3 mg/d)
Trial: 37930781
Drug: Lumen voice-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumen voice-based coach delivering 8 problem-solving treatment sessions
Trial: 37930792
Drug: Increased daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased daily documented total activity time
Trial: 37931185
Drug: Circulating tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating tumor cell count-driven therapy
Trial: 37931304
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy - Taking it Further (MBCT-TiF)
Trial: 39252547
Drug: eIMPACT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Trial: 37931632
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with pembrolizumab (n=222)
Trial: 37931632
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (n=218)
Trial: 37931634
Drug: Sparsentan (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparsentan (400 mg oral once daily)
Trial: 37931634
Drug: Irbesartan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (300 mg oral once daily)
Trial: 37932009
Drug: Remibrutinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib (100 mg, one or two times a day)
Trial: 37932258
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 1 mg
Trial: 37932258
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 3 mg
Trial: 37932258
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 6 mg
Trial: 37932258
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 10 mg
Trial: 37932258
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 (≥3 mg)
Trial: 37932443
Drug: Irinotecan dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan dosage adjusted based on UGT1A1 polymorphisms, specifically 370 mg/m² for *1/*1 genotype.
Trial: 37932443
Drug: Irinotecan dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan dosage adjusted based on UGT1A1 polymorphisms.
Trial: 37932443
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of irinotecan (180 mg/m²).
Trial: 37932589
Drug: mesoglycan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesoglycan 50 mg bid
Trial: 37932739
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg suramin
Trial: 37932739
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg suramin
Trial: 37932787
Drug: POINCARE-2 strategy
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POINCARE-2 strategy (daily weighing over 14 days, restriction of fluid intake, administration of diuretics, and/or ultrafiltration)
Trial: 37932812
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion (500-mL saline infusion)
Trial: 37932812
Drug: Norepinephrine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine dose increase
Trial: 37933546
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (survey administered)
Trial: 37933546
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no survey administered)
Trial: 37934301
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) (3 sessions for 3 weeks, once a week, 1.8 bar, 10.0 Hz, 2000 impulses)
Trial: 37934400
Drug: Individualized mat-Pilates
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized mat-Pilates sessions (45 min, twice weekly)
Trial: 37934530
Drug: Specialty TUD
RxNorm normalized name: Tudorza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialty TUD services (including behavioral counseling and medications for tobacco treatment)
Trial: 37934566
Drug: DWELL intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DWELL intervention (Facebook group providing practical solutions for home design for wellness)
Trial: 37934611
Drug: Ceralasertib (AZD6738)
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib (AZD6738) 160 mg twice daily for 2 weeks in a 4-weekly cycle
Trial: 37934611
Drug: Ceralasertib (AZD6738)
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib (AZD6738) at doses of 20-240 mg BD continuously or intermittently
Trial: 37935109
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (≤20 ng/mL)
Trial: 37935416
Drug: Cognitively stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitively stimulating semistructured conversations via internet/webcam 4 times per week for 6 months, then twice per week for an additional 6 months; plus weekly 10 minutes telephone check-ins
Trial: 37935416
Drug: Weekly 10
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 10 minutes telephone check-ins
Trial: 37935524
Drug: Niraparib in
RxNorm normalized name: Product containing niraparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib in combination with bevacizumab after carboplatin/paclitaxel
Trial: 37935531
Drug: G-CBT (group-cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CBT (group-cognitive behavioral therapy)
Trial: 37935631
Drug: Abemaciclib in
RxNorm normalized name: Product containing abemaciclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib in combination with fulvestrant
Trial: 37935977
Drug: Idarubicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin with higher dose cytarabine (IA)
Trial: 37935977
Drug: Idarubicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin with higher dose cytarabine and vorinostat (IA+V)
Trial: 37935977
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose cytarabine (with or without vorinostat)
Trial: 37936136
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of drugs and duration of illness
Trial: 37936166
Drug: Anlotinib 12
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities
Trial: 37936331
Drug: Antibacterial therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapeutic clothing (chitosan) + standard topical treatment
Trial: 37936331
Drug: Antibacterial therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapeutic clothing (silver) + standard topical treatment
Trial: 37936331
Drug: Standard therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapeutic clothing + standard topical treatment
Trial: 37936408
Drug: Long-acting muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonist therapy
Trial: 37936551
Drug: Adherence support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence support strategies including monthly counselling sessions with drug-level feedback (DLF), optional daily SMS reminders, weekly phone or SMS check-ins, peer support clubs, and additional counselling.
Trial: 37936551
Drug: In-person clubs
RxNorm normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person clubs and weekly calls as support strategies.
Trial: 37936652
Drug: Monovalent SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (10 μg of the spike protein from the ancestral D614 strain)
Trial: 37936652
Drug: Monovalent SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant
Trial: 37936687
Drug: QL1604 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1604 at 3 mg/kg Q2W
Trial: 37936687
Drug: QL1604 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1604 at 3 mg/kg (Q2W and Q3W) and 200 mg (Q3W)
Trial: 37936786
Drug: Anplag® 90mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anplag® 90mg (Ticagrelor) tablet